| Description |
Publish Date |
LINKS |
Important safety information on Dolutegravir in Lebanon
|
10/10/2018
|
|
Important safety information on Lamotrigine in Lebanon
|
10/10/2018 |
|
| Important safety information on Abacavir: Hypersensitivity reaction - educational slide deck |
15/02/2024
|
|
| Important safety information on Non-steroidal anti-inflammatory drugs (NSAlDs) in Lebanon |
11/06/2021 |
|
Important safety information on Amoxicillin / Amoxicillin and clavulanic acid containing products in Lebanon |
09/09/2023 |
|
| Important safety information on Dolutegravir in Lebanon (Safety Notification_Korean label update for Dolutegravir containing products) |
01-11-2023 |
|
| Important safety information on Paroxetine in Lebanon (Safety Notification_EMA communication issued relating to Paroxetine label update) |
27-10-2023 |
|
| Important safety information on Sumatriptan in Lebanon (Safety Notification_Sumatriptan and breast pain) |
07-11-2023 |
|
| Important safety information on Topical Corticosteroids containing products in Lebanon |
15-11-2023 |
|
| Important safety information on Hepatitis B surface antigen recombinant vaccine in Lebanon (Initial Safety Notification Engerix-B and Myelitis_November 2023) |
17-11-2023 |
|
| Important safety information on Hepatitis B surface antigen recombinant vaccine in Lebanon (Updated Safety Notification Engerix-B and Myelitis_December 2023) |
02-01-2024 |
|
Important safety information on Amoxicillin/clavulanic acid containing products - MedSafe communication regarding labelling updates |
18/12/2023 |
|
Important safety information on Zanamivir containing products - Precautions for prescribing and administering flu medications (zanamivir) |
26/12/2023 |
|
Important safety information on Paroxetine containing products - Modifications of the information of medicines authorized by national procedure that contain Paroxetine_NPCV |
03/01/2024 |
|
Important safety information on Acyclovir containing products - Safety Notification EMA-PRAC: The MAH has been requested to provide cumulative reviews of the below-mentioned issues in the next PBRER to be submitted for acyclovir |
02/01/2024 |
|
Important safety information on Levetiracetam containing products - FDA Warns of Rare but Serious Drug Reaction - Keppra |
03/01/2024 |
|
Important safety information on Hepatitis B surface antigen recombinant vaccine (Updated Safety Notification Engerix-B and Myelitis_January 2024) |
25/01/2024 |
|
Important safety information on Lamotrigine containing products - Latest Prescriber Update (vol 45:1 March 2024) received from Medsafe |
18/03/2024 |
|
Important safety information on Abacavir containing products - Regarding amendments to the instructions for medical use of medicines containing abacavir |
19/03/2024 |
|
Important safety information on Lamotrigine containing products - Safety Signal received from Swissmedic: Lamictal - Interaction with hormone replacement therapies (HRT) |
04/04/2024 |
|
Important safety information on Hepatitis B surface antigen recombinant vaccine - Updated Safety Notification Engerix-B and Myelitis_May 2024 |
07/05/2024 |
|
